{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:13:11Z","timestamp":1790136791452,"version":"4.0.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.vaccine.2022.02.081","type":"journal-article","created":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T16:50:53Z","timestamp":1647622253000},"page":"2635-2646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay"],"prefix":"10.1016","volume":"40","author":[{"given":"Jason J.","family":"LeBlanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"ElSherif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"MacKinnon-Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardith","family":"Ambrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd F.","family":"Hatchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.S.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley D.","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter H.B.","family":"Demczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa K.","family":"Andrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bowie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne E.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"McGeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makeda","family":"Semret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Trottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Valiquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly A.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2022.02.081_b0005","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1099\/jmm.0.000097","article-title":"Detection and prediction of Streptococcus pneumoniae serotypes directly from nasopharyngeal swabs using PCR","volume":"64","author":"Lang","year":"2015","journal-title":"J Med Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.081_b0010","doi-asserted-by":"crossref","first-page":"e0220453","DOI":"10.1371\/journal.pone.0220453","article-title":"Limited indirect effects of an infant pneumococcal vaccination program in an aging population","volume":"14","author":"van der Linden","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.02.081_b0015","unstructured":"Public Agency of Canada (PHAC). National laboratory surveillance of invasive streptococcal disease in Canada. Annual summary 2018. https:\/\/publications.gc.ca\/collections\/collection_2021\/aspc-phac\/HP57-4-2018-eng.pdf [last accessed Feb. 10, 2022]."},{"issue":"31","key":"10.1016\/j.vaccine.2022.02.081_b0020","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1016\/j.vaccine.2018.06.018","article-title":"Serotype distribution of invasive Streptococcus pneumoniae in adults 65 years of age and over after the introduction of childhood 13-valent pneumococcal conjugate vaccination programs in Canada, 2010\u20132016","volume":"36","author":"Demczuk","year":"2018","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.vaccine.2022.02.081_b0025","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1016\/j.vaccine.2021.02.069","article-title":"Invasive pneumococcal disease in Canada 2010\u20132017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines","volume":"39","author":"Dion","year":"2021","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.081_b0030","doi-asserted-by":"crossref","first-page":"e0226353","DOI":"10.1371\/journal.pone.0226353","article-title":"The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007\u20132017","volume":"14","author":"Wijayasri","year":"2019","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.081_b0035","article-title":"Age-stratified burden of pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2015","volume":"7","author":"LeBlanc","year":"2020","journal-title":"BMJ Open Respir Res"},{"issue":"36","key":"10.1016\/j.vaccine.2022.02.081_b0040","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1016\/j.vaccine.2019.05.003","article-title":"Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN)","volume":"37","author":"LeBlanc","year":"2019","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2022.02.081_b0045","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1016\/j.vaccine.2017.05.049","volume":"35","author":"LeBlanc","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.081_b0050","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.081_b0055","doi-asserted-by":"crossref","first-page":"e60273","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques","volume":"8","author":"Said","year":"2013","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.081_b0060","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1183\/09031936.00183614","article-title":"Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia","volume":"45","author":"Rodrigo","year":"2015","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.081_b0065","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.02.081_b0070","doi-asserted-by":"crossref","unstructured":"Torres A, Men\u00e9ndez R, Espa\u00f1a PP, Fern\u00e1ndez-Villar JA, Marim\u00f3n JM, Cilloniz C, et al.. The evolution and distribution of pneumococcal serotypes in adults hospitalized with community acquired pneumonia in Spain using serotype specific urinary antigen detection test: the CAPA study, 2011-2018. Clin Infect Dis. 2021 Apr 14:ciab307. doi: 10.1093\/cid\/ciab307. PMID: 33851220.","DOI":"10.1093\/cid\/ciab307"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.081_b0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/thoraxjnl-2019-213725","article-title":"Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013\u201318","volume":"75","author":"Pick","year":"2020","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.081_b0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10096-014-2209-5","article-title":"Bacteraemic and non-bacteraemic\/urinary antigen-positive pneumococcal community-acquired pneumonia compared","volume":"34","author":"van Mens","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"39","key":"10.1016\/j.vaccine.2022.02.081_b0085","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1016\/j.vaccine.2017.08.007","article-title":"The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test","volume":"35","author":"Men\u00e9ndez","year":"2017","journal-title":"CAPA study Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.081_b0090","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/cid\/cix1066","article-title":"Pneumococcal community-acquired pneumonia detected by serotype-specific urinary antigen detection assays","volume":"66","author":"Wunderink","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.081_b0095","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.vaccine.2018.02.005","article-title":"13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups","volume":"36","author":"Daniel","year":"2018","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.02.081_b0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/23744235.2020.1772991","article-title":"Non-bacteremic pneumococcal pneumonia: general characteristics and early predictive factors for poor outcome","volume":"52","author":"Serrano","year":"2020","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.vaccine.2022.02.081_b0105","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2018.02.007","article-title":"Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review","volume":"137","author":"Torres","year":"2018","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.081_b0110","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-017-0552-x","article-title":"Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults","volume":"17","author":"Storms","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.vaccine.2022.02.081_b0115","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy312","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: A test-negative design","author":"McLaughlin","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.081_b0120","first-page":"1900","article-title":"Risk of hospitalization due to pneumococcal disease in adults in Spain","volume":"12","author":"Gil-Prieto","year":"2016","journal-title":"The CORIENNE study Hum Vaccin Immunother"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2022.02.081_b0125","doi-asserted-by":"crossref","first-page":"756","DOI":"10.17269\/s41997-018-0050-9","article-title":"Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults","volume":"109","author":"Atwood","year":"2018","journal-title":"Can J Public Health"},{"issue":"18","key":"10.1016\/j.vaccine.2022.02.081_b0130","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.081_b0135","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1080\/21645515.2018.1428507","article-title":"Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium","volume":"14","author":"Willem","year":"2018","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.081_b0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10900-019-00716-8","article-title":"Cost-Effectiveness of pneumococcal vaccination and uptake improvement programs in underserved and general population adults aged < 65 Years","volume":"45","author":"Wateska","year":"2020","journal-title":"J Community Health"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.081_b0145","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/21645515.2018.1564439","article-title":"An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis","volume":"15","author":"Wateska","year":"2019","journal-title":"Human Vaccines & Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2022.02.081_b0150","unstructured":"National Advisory Committee on Immunization (NACI). https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci.html [last accessed Feb. 10, 2022]."},{"issue":"46","key":"10.1016\/j.vaccine.2022.02.081_b0155","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-Valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 Years: Updated recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2022.02.081_b0160","unstructured":"Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822-5. PMID: 25233284; PMCID: PMC5779453."},{"key":"10.1016\/j.vaccine.2022.02.081_b0165","doi-asserted-by":"crossref","first-page":"e2477","DOI":"10.7717\/peerj.2477","article-title":"Whole genome sequencing of Streptococcus pneumoniae: development, evaluation and verification of targets for serogroup and serotype prediction using an automated pipeline","volume":"4","author":"Kapatai","year":"2016","journal-title":"PeerJ"},{"issue":"45","key":"10.1016\/j.vaccine.2022.02.081_b0170","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1016\/j.vaccine.2018.03.012","article-title":"Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-na\u00efve adults \u226550 years of age","volume":"36","author":"Ermlich","year":"2018","journal-title":"Vaccine"},{"issue":"42","key":"10.1016\/j.vaccine.2022.02.081_b0175","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1016\/j.vaccine.2019.08.048","article-title":"Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults","volume":"37","author":"Thompson","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.081_b0180","doi-asserted-by":"crossref","first-page":"18977","DOI":"10.1038\/s41598-020-75691-5","article-title":"Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency","volume":"10","author":"L\u00f8chen","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.081_b0185","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/cid\/ciy800","article-title":"Decline in pneumococcal disease attenuated in older adults and those with comorbidities following universal childhood PCV13 immunization","volume":"68","author":"Pelton","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.02.081_b0190","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1080\/21645515.2019.1690884","article-title":"Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain","volume":"16","author":"Rivero-Calle","year":"2020","journal-title":"Hum Vaccin Immunother"},{"issue":"49","key":"10.1016\/j.vaccine.2022.02.081_b0195","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1016\/j.vaccine.2013.09.049","article-title":"Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995\u20132011","volume":"31","author":"Rudnick","year":"2013","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.02.081_b0200","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.02.081_b0205","unstructured":"Public Health Agency of Canada (PHAC). Vaccine coverage in Canadian children. Results from the 2017 childhood national immunization coverage survey (cNICS). Dec. 2019. https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/documents\/services\/publications\/healthy-living\/2017-vaccine-uptake-canadian-children-survey\/2017-vaccine-uptake-canadian-children-survey-eng.pdf [last accessed Feb 10, 2022]."},{"key":"10.1016\/j.vaccine.2022.02.081_b0210","unstructured":"Public Health Agency of Canada (PHAC). Vaccine uptake in Canadian adults. Results from the 2016 adult national immunization coverage survey (aNICS). July 2018. https:\/\/publications.gc.ca\/collections\/collection_2018\/aspc-phac\/HP40-222-2018-eng.pdf [last accessed Feb 10, 2022]."},{"issue":"10","key":"10.1016\/j.vaccine.2022.02.081_b0215","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12325-014-0157-1","article-title":"Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe","volume":"31","author":"Castiglia","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.vaccine.2022.02.081_b0220","doi-asserted-by":"crossref","unstructured":"Regev-Yochay G, Chowers M, Chazan B, Gonzalez E, Gray S, Zhang Z, et al. Distribution of 13-valent pneumococcal conjugate vaccine serotype Streptococcus pneumoniae in adults 50 years and older presenting with community-acquired pneumonia in Israel. Hum Vaccin Immunother. 2018;14(10):2527-2532. doi: 10.1080\/21645515.2018.1475811. Epub 2018 Sep 6. PMID: 30188760; PMCID: PMC6284513.","DOI":"10.1080\/21645515.2018.1475811"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.081_b0225","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/infdis\/jit506","article-title":"Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged \u226550 years with community-acquired pneumonia","volume":"208","author":"Sherwin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.02.081_b0230","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa158","article-title":"Qualification and clinical validation of an immunodiagnostic assay for detecting 11 additional Streptococcus pneumoniae serotype-specific polysaccharides in human urine","author":"Kalina","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.02.081_b0235","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1128\/CVI.00064-12","article-title":"Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine","volume":"19","author":"Pride","year":"2012","journal-title":"Clin Vaccine Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.02.081_b0240","doi-asserted-by":"crossref","first-page":"115282","DOI":"10.1016\/j.diagmicrobio.2020.115282","article-title":"Comparison of PCV-10 and PCV-13 vaccine coverage for invasive pneumococcal isolates obtained across Canadian geographic regions, SAVE 2011 to 2017","volume":"99","author":"Hink","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.081_b0245","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.vaccine.2019.11.026","article-title":"CAPNETZ study group. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia","volume":"38","author":"Forstner","year":"2020","journal-title":"Vaccine"},{"issue":"30","key":"10.1016\/j.vaccine.2022.02.081_b0250","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1016\/j.vaccine.2019.05.065","article-title":"A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands","volume":"37","author":"Gessner","year":"2019","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.02.081_b0255","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3201\/eid2707.204403","article-title":"Whole-Genome analysis of Streptococcus pneumoniae serotype 4 causing outbreak of invasive pneumococcal disease, Alberta","volume":"27","author":"Kellner","year":"2021","journal-title":"Canada Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.02.081_b0260","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/infdis\/jix282","article-title":"The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People","volume":"216","author":"Andrew","year":"2017","journal-title":"J Infect Dis"},{"issue":"43","key":"10.1016\/j.vaccine.2022.02.081_b0265","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1016\/j.vaccine.2019.08.059","article-title":"Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis","volume":"37","author":"McLaughlin","year":"2019","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2022.02.081_b0270","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/EDE.0000000000001135","article-title":"Estimating serotype-specific efficacy of pneumococcal conjugate vaccines using hierarchical models","volume":"31","author":"Warren","year":"2020","journal-title":"Epidemiology"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.081_b0275","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40121-021-00406-w","article-title":"Pneumococcal conjugate vaccine impact on serotype 3: A review of surveillance data","volume":"10","author":"Sings","year":"2021","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.081_b0280","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/microorganisms10010127","article-title":"PCV13 vaccination of adults against pneumococcal disease: What we have learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)","volume":"10","author":"Theilacker","year":"2022","journal-title":"Microorganisms"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22002468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:11:56Z","timestamp":1759403516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22002468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":56,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0264410X22002468"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.081","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}